Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 1, 2009, Pages 107-113

  Brüggemann, Roger J M ^a   Blijlevens, N M A ^a   Burger, David M ^a   Franke, Barbara ^a   Troke, Peter F ^b   Donnelly, J Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b The Old Court ^*  (United Kingdom)

Author keywords

Azole antifungal drugs; Clinical pharmacology; Drug exposure; Haematology

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; CYCLOSPORIN A; CYTOCHROME P450 2C19; VORICONAZOLE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COLD SENSATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ECG ABNORMALITY; EVENING DOSAGE; FEMALE; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC POLYMORPHISM; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEAT SENSATION; HETEROZYGOTE; HUMAN; HYPERBILIRUBINEMIA; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MYCOSIS; NAUSEA; NEPHROTOXICITY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; SEPSIS; SIDE EFFECT; STEADY STATE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL DISORDER; VISUAL HALLUCINATION; VOMITING;

EID: 77950350220     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp416     Document Type: Article

References (27)

1. Balian JD, Sukhova N, Harris JW et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57: 662-9.
2. Pfaller MA. Invasive fungal pathogens: current epidemiological trends. Clin Infect Dis 2006; 43.
3. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-66.
4. Morgan J, Wannemuehler KA, Marr KA et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 Suppl 1: S49-58.
5. Upton A, Kirby KA, Carpenter P et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-40.
6. Groll AH, Kolve H, Ehlert K et al. Pharmacokinetic interaction between voriconazole and ciclosporin A following allogeneic bone marrow transplantation. J Antimicrob Chemother 2004; 53: 113-4.
7. Romero AJ, Le PP, Nilsson LG et al. Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients. Clin Pharmacol Ther 2002; 71: 226-34.
8. Kahan BD. Cyclosporine: a revolution in transplantation. Transplant Proc 1999; 31: p14S-5S.
9. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31: 540-7.
10. Bruggemann RJ, Touw DJ, Aarnoutse RE et al. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009; 53: 303-5.
11. Ronaghi M. Pyrosequencing for SNP genotyping. Methods Mol Biol 2003; 212: 189-95.
12. Johnston A. The pharmacokinetics of voriconazole. Br J Clin Pharmacol 2003; 56 Suppl 1: 1.
13. Lazarus HM, Blumer JL, Yanovich S et al. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol 2002; 42: 395-402.
14. Purkins L, Wood N, Ghahramani P et al. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.
15. Purkins L, Wood N, Greenhalgh K et al. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent. Br J Clin Pharmacol 2003; 56 Suppl 1: 2-9.
16. Imhof A, Schaer D, Schanz U et al. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136: 739-42.
17. Tan K, Brayshaw N, Tomaszewski K et al. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006; 46: 235-43.
18. Zonios DI, Gea-Banacloche J, Childs R et al. Hallucinations during voriconazole therapy. Clin Infect Dis 2008; 47: e7-10.
19. von Mach MA, Burhenne J, Weilemann LS. Accumulation of the solvent vehicle sulphobutylether beta cyclodextrin sodium in critically ill patients treated with intravenous voriconazole under renal replacement therapy. BMC Clin Pharmacol 2006; 6:6.
20. Alvarez-Lerma F, Allepuz-Palau A, Garcia MP et al. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother 2008; 20: 93-100.
21. Trifilio SM, Bennett CL, Yarnold PR et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007; 39: 425-9.
22. Geist MJ, Egerer G, Burhenne J et al. Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype. Antimicrob Agents Chemother 2006; 50: 3227-8.
23. Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
24. Smith J, Safdar N, Knasinski V et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570-2.
25. Trifilio S, Ortiz R, Pennick G et al. Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2005; 35: 509-13.
26. Lewis RE. What is the "therapeutic range" for voriconazole? Clin Infect Dis 2008; 46: 212-4.
27. Denning DW, Ribaud P, Milpied N et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.